Skip to content
Screener

BioMarin Pharmaceuticals BMRN Cash & Equivalents

Cash & Equivalents at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$571.15M+11.9%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$833.99M-43.7%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$145.32M+205%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$99.65M+23.2%
Regenxbio logo
RegenxbioRGNX
$36.49M-54.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$882.02M+62.5%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016

FAQ

What is BioMarin Pharmaceuticals's cash & equivalents?
BioMarin Pharmaceuticals (BMRN) reported cash & equivalents of $874.01M in Q2 2026.
How has BioMarin Pharmaceuticals's cash & equivalents changed year-over-year?
BioMarin Pharmaceuticals's cash & equivalents decreased by 28.0% year-over-year, from $1.21B to $874.01M.
What is the long-term trend for BioMarin Pharmaceuticals's cash & equivalents?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's cash & equivalents has grown at a 15.1% compound annual growth rate (CAGR), from $649.16M to $1.31B.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about BioMarin Pharmaceuticals's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude